EXELIXIS, INC.
EXEL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for EXEL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EXEL
Exelixis is an oncology company with four marketed products, including cabozantinib-based therapies, and a pipeline led by zanzalintinib, which is under FDA review for colorectal cancer. The company reported $628.7M in revenue and $212.1M in net income as of mid-2026.
Key risk: Clinical trial cost increases
BioSniper Score
Based on 6 of 6 signals
Market Cap
$13.49B
Cash Runway
7.8 moLead Asset
CABOMETYX (Approved)Next Catalyst
Phase1_Start · Sep 30, 2026Financial data as of Jul 3, 2026.
Tracking 5 pipeline candidates · 11 clinical trials · 9 catalysts · 2 FDA decisions for EXELIXIS, INC..
Similar companies
Exelixis is an oncology company with four marketed products, including cabozantinib-based therapies, and a pipeline led by zanzalintinib, which is under FDA review for colorectal cancer. The company reported $628.7M in revenue and $212.1M in net income as of mid-2026.
- Exelixis has four marketed pharmaceutical products, including two formulations of cabozantinib (COMETRIQ and CABOMETYX) [sec_mda · as of 2026-08-05].
- Lead clinical asset zanzalintinib is under FDA review for certain forms of colorectal cancer and is the focus of an extensive late-stage clinical program [sec_mda · as of 2026-08-05].
- As of 2026-07-03, the company reported cash & equivalents of $281.4M, total revenue of $628.7M, net income of $212.1M, and shareholders' equity of $2,161.3M [sec].
- The pipeline includes multiple biotherapeutics and small molecule programs, with ADC XB773 targeting DLL3 expected to progress toward an IND filing in 2026 [sec_mda · as of 2026-08-05].
- Exelixis is prioritizing investment in new molecules such as zanzalintinib, XB010, XB628, and XB371, with clinical trial costs projected to increase for the remainder of 2026 [sec_mda · as of 2026-08-05].
What works
- Exelixis has a strong commercial foundation with four marketed products generating significant revenue, including $628.7M in total revenue as of 2026-07-03 [sec].
- The company maintains a disciplined investment approach and a robust pipeline, with zanzalintinib under FDA review and multiple late-stage trials underway [sec_mda · as of 2026-08-05].
- Exelixis has established multiple research collaborations and in-licensing arrangements to access antibodies, binders, payloads, and conjugation technologies for next-generation ADCs and multispecific antibodies [sec_mda · as of 2026-08-05].
What to weigh
- Clinical trial costs are projected to increase for the remainder of 2026, driven by higher costs for studies evaluating zanzalintinib, XB628, and XB371 [sec_mda · as of 2026-08-05].
- The company's pipeline includes early-stage assets with no guarantee of clinical or commercial success, and many programs are still in preclinical or early clinical stages [sec_mda · as of 2026-08-05].
- Patent exclusivity for key products COMETRIQ and CABOMETYX is set to expire in 2032 and 2033, respectively, which could impact future revenue [catalyst_timeline].
From the filings
Quoted directly from source documents.
Exelixis has four marketed products, including two formulations of cabozantinib.
“We have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib”
SEC MD&A · August 5, 2026
Zanzalintinib is under FDA review for colorectal cancer.
“our lead clinical asset, zanzalintinib, currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of certain forms of colorectal cancer (CRC)”
SEC MD&A · August 5, 2026
XB773 is an ADC targeting DLL3 expected to progress toward an IND filing in 2026.
“expect to progress XB773, an ADC targeting the tumor antigen DLL3 toward a potential IND filing in 2026”
SEC MD&A · August 5, 2026
Catalyst timeline
- 2026-09-30 · Phase 1 Start for XL092 in pediatric solid tumors — A Phase 1 dose-escalation study of XL092 in children and adolescents with relapsed or refractory solid tumors.
- 2027-01-31 · Phase 3 Topline for XL092 + atezolizumab vs regorafenib — A randomized open-label Phase 3 study of XL092 + atezolizumab vs regorafenib in metastatic colorectal cancer.
- 2028-06-30 · Phase 3 Topline for XL092 + nivolumab vs sunitinib — A randomized open-label Phase 3 study of XL092 + nivolumab vs sunitinib in advanced renal cell carcinoma.
- 2029-06-30 · Phase 3 Topline for zanzalintinib vs everolimus — A Phase 2/3 study of zanzalintinib vs everolimus in advanced solid tumors.
- 2030-04-05 · Phase 3 Topline for zanzalintinib ± pembrolizumab — Randomized Phase 3 study of zanzalintinib ± subcutaneous pembrolizumab and berahyaluronidase alfa.
- 2030-05-31 · Phase 3 Topline for long-term extension study — Long-term extension study for participants previously enrolled in an Exelixis-sponsored study.
- 2032-02-10 · Patent expiry for COMETRIQ — Patent/exclusivity expiry for COMETRIQ.
- 2033-07-09 · Patent expiry for CABOMETYX — Patent/exclusivity expiry for CABOMETYX.
Risks & what to watch (3)›
Key risks
- Clinical trial cost increases — Clinical trial costs may increase for the remainder of 2026, driven by studies for zanzalintinib, XB628, and XB371 [sec_mda · as of 2026-08-05].
- Pipeline stage uncertainty — Many pipeline assets are preclinical or early clinical, with no guarantee of success [sec_mda · as of 2026-08-05].
- Patent expirations for key products — Patent/exclusivity for COMETRIQ expires in 2032 and for CABOMETYX in 2033 [catalyst_timeline].
What to watch
- FDA decision on zanzalintinib for colorectal cancer [sec_mda · as of 2026-08-05].
- Progress of XB773 ADC toward IND filing in 2026 [sec_mda · as of 2026-08-05].
- Phase 3 topline results for zanzalintinib in various indications starting in 2027 [catalyst_timeline].
- Potential new development candidates reaching preclinical status in 2026 and beyond [sec_mda · as of 2026-08-05].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run EXELIXIS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available EXELIXIS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
7.8 months
D/E 0.35 · 4% dilution
Lead: Approved
5 candidates
9 upcoming, next in ~31d
0 buys · 10 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 16.2%
- Days to cover
- 13.1
- Shares short
- 30,010,146
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EXEL short interestGovernance
Frequently asked questions
What is the AI investment thesis for EXELIXIS, INC.?
Exelixis is an oncology company with four marketed products, including cabozantinib-based therapies, and a pipeline led by zanzalintinib, which is under FDA review for colorectal cancer. The company reported $628.7M in revenue and $212.1M in net income as of mid-2026.
What is EXELIXIS, INC.'s lead drug candidate?
EXELIXIS, INC.'s most advanced tracked candidate is CABOMETYX (Approved) for Advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), differentiated thyroid cancer (DTC), pancreatic neuroendocrine tumors (pNET), extra-pancreatic neuroendocrine tumors (epNET).
What is EXELIXIS, INC.'s next catalyst?
EXELIXIS, INC.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase 1 Dose-Escalation Study of XL092 in Children and Adolescents With Relapsed or Refractory Sol" — expected September 30, 2026.
Who is the CEO of EXELIXIS, INC.?
Dr. Michael M. Morrissey Ph.D. is the chief executive officer of EXELIXIS, INC. (EXEL).
Where is EXELIXIS, INC. headquartered?
EXELIXIS, INC. (EXEL) is headquartered in Alameda, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.